Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners is well positioned to benefit from its scale as the nation’s fifth largest ASC system and the only remaining independent platform, with 120 consolidated facilities and a valuation around 13.7x pro forma ’26 AEBITDA. The Idaho Falls divestiture materially improves the profile by sharpening its pure-play short-stay surgical focus, lowering Medicaid exposure below 2%, and delivering roughly 30bps of deleveraging plus stronger earnings-to-cash conversion. With updated FY26 guidance of $2.60-$2.67B in pro forma revenue and at least $414MM in adjusted EBITDA, the company also retains upside from high-acuity procedure growth, Medicare rule changes, and disciplined physician recruitment.

Surgery Partners is تواجه a negative outlook because its business is exposed to multiple structural risks, including competition from office-based physicians, other specialized providers and health systems, dependence on managed care and Medicare payment rates, and revenue concentration. Its highly levered balance sheet, combined with integration risk from acquisition-driven growth and the need to recruit and retain physicians and clinical labor, raises execution risk just as staffing costs and turnover are pressuring margins. Although demand and patient volume have recently recovered, reimbursement generally lags costs, CMS has issued more onerous provisions, and a recession could weaken elective ambulatory care volumes and limit revenue growth.